Dermatology
News from the FDA/CDC
Intravenous formulation of secukinumab gets FDA approval
This new route of administration is expected to become available during the fourth quarter of 2023.
From the Journals
More evidence shows COVID-19’s link to risk for autoimmune disease
Patients with more severe COVID-19 that required hospitalization in the ICU were more likely to develop vasculitis, alopecia totalis, and several...
Latest News
Choosing which biologic to prescribe for psoriasis
In cases of primary failure, consider revisiting the diagnosis, Dr. April Armstrong advised.
Latest News
Spironolactone safe, effective option for women with hidradenitis suppurativa
“Combining different treatment options that target different pathophysiologic factors is usually required to achieve adequate disease control in...
Commentary
Can zoo poo help manage diabetic foot ulcers?
The unexpected ingredient in this potentially transformative therapy? Feces from endangered species, sourced from Yorkshire Wildlife Park.
Latest News
FDA issues letter regarding lebrikizumab review for atopic dermatitis
The agency cited concerns related to an inspection of a third-party contract manufacturer.
Latest News
Study finds inflammatory bowel disease risk higher in children, adults with atopic dermatitis
AD has been associated with an increasing number of comorbidities, including IBD, but studies linking AD with IBD have had mixed results,...
Latest News
These adverse events linked to improved cancer prognosis
Emerging evidence suggests that cutaneous immune-related adverse events may be linked with favorable outcomes among patients with cancer who...
Latest News
Does the number of primary melanomas affect survival?
To compare 10-year melanoma-specific mortality and overall mortality between people with multiple primary melanomas and a single primary melanoma...
From the Journals
Hidradenitis suppurativa experts reach consensus on treatment outcome measures
“The intent of these recommendations is to provide an objective framework with both clinician and patient input that can facilitate bidirectional...
Latest News
Most adults with alopecia areata untreated 1 year after diagnosis
During the first year after diagnosis, 66.4% of patients received at least one treatment for AA at one or more time points.